Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07168200
PHASE3

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).

Official title: A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

720

Start Date

2025-10-17

Completion Date

2028-12

Last Updated

2025-11-17

Healthy Volunteers

No

Interventions

DRUG

SHR-1316 Injection

SHR-1316 injection.

DRUG

Cisplatin Injection

Cisplatin injection.

DRUG

Carboplatin Injection

Carboplatin injection.

DRUG

Paclitaxel Injection

Paclitaxel injection.

DRUG

SHR-1316 Placebo Injection

SHR-1316 placebo injection.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China